Reversal of Taxol resistance in hepatoma by cyclosporin A: involvement of the PI-3 kinase-AKT 1 pathway
2003

Reversal of Taxol Resistance in Liver Cancer Cells

Sample size: 5 publication 10 minutes Evidence: moderate

Author Information

Author(s): H-L Lin, W-Y Lui, T-Y Liu, C-W Chi

Primary Institution: National Yang-Ming University

Hypothesis

Can cyclosporin A enhance the effectiveness of Taxol in treating Taxol-resistant hepatoma cells?

Conclusion

The combination of cyclosporin A and Taxol effectively reverses Taxol resistance in hepatoma cells both in vitro and in vivo.

Supporting Evidence

  • Cyclosporin A combined with Taxol showed enhanced cytotoxicity in hepatoma cells.
  • The study demonstrated that the PI3 kinase-AKT1 pathway is involved in Taxol resistance.
  • In vivo experiments showed significant tumor growth inhibition with the combination treatment.

Takeaway

This study found that using cyclosporin A with Taxol can help liver cancer cells respond better to treatment, which is usually very hard to do.

Methodology

The study involved in vitro and in vivo experiments using various hepatoma cell lines and mouse models to assess the effects of cyclosporin A and Taxol on cell viability and tumor growth.

Potential Biases

Potential bias in the selection of cell lines and animal models used for the experiments.

Limitations

The study primarily focused on specific cell lines and may not fully represent all hepatocellular carcinoma cases.

Participant Demographics

The study used human hepatoma cell lines and male SCID and C57BL/6 mice.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6600788

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication